Turning Point Therapeutics

$117.91
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

+$1.00 (+0.86%) Today
$0.00 (0.00%) As of 1:00 AM UTC after-hours

Why Robinhood?

You can buy or sell TPTX and other stocks, options, and ETFs commission-free!

About TPTX

Turning Point Therapeutics, Inc. engages in the discovery and development of precision medicines for cancer and other diseases. Its product pipeline include Repotrectinib, TPX-0022, TPX-0046, and TPS-O131, a next-gen ALK inhibitor. The company was founded by J. Jean Cui and Y. Peter Li in October 2013 and is headquartered in San Diego, CA. The listed name for TPTX is Turning Point Therapeutics, Inc. Common Stock.

CEO
Athena Countouriotis
Employees
95
Headquarters
San Diego, California
Founded
2013
Market Cap
5.70B
Price-Earnings Ratio
—
Dividend Yield
—
Average Volume
257.88K
High Today
$119.91
Low Today
$110.84
Open Price
$118.23
Volume
291.63K
52 Week High
$141.30
52 Week Low
$31.30

TPTX Earnings

-$0.92
-$0.61
-$0.31
$0.00
Q2 FY19
Q3 FY19
Q4 FY19
Q1 FY20
Q2 FY20
Q3 FY20
Q4 FY20
Estimated
-$0.92 per share
Actual
Available Mar 1, After Hours

You May Also Like

CLOV
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, a registered broker-dealer and Member SIPC. Full disclosure